search button
Open Access

Epsin 3 potentiates the NF‑κB signaling pathway to regulate apoptosis in breast cancer

  • Authors:
    • Qianxue Wu
    • Qing Li
    • Wenming Zhu
    • Xiang Zhang
    • Hongyuan Li

  • View Affiliations

  • Published online on: November 11, 2021     https://doi.org/10.3892/mmr.2021.12531
  • Article Number: 15

  • Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Endocrine drug resistance is common in some patients with estrogen receptor (ER)‑positive breast cancer, so it is necessary to identify potential therapeutic targets. The aim of the present study was to investigate the regulatory effect and mechanism of epsin 3 (EPN3) expression level changes on the proliferation and apoptosis of ER‑positive breast cancer. Online GEPIA was used to analyze the expression level of EPN3 in breast cancer. The online Kaplan‑Meier plotter tool was used to analyze the relationship between EPN3 expression and the prognosis of patients with breast cancer. Reverse transcription‑quantitative PCR, immunohistochemistry and western blotting were performed to detect the mRNA and protein expression levels of EPN3 in breast cancer tissues and cells. A lentiviral infection system was used to knockdown the expression of EPN3 in breast cancer cell lines. Cell Counting Kit‑8 and flow cytometry assays were conducted to detect the effect of EPN3 knockdown on breast cancer cell proliferation and apoptosis. Western blotting was used to detect the regulation of EPN3 expression on NF‑κB, and immunofluorescence was performed to detect the effect of EPN3 expression on NF‑κB nuclear translocation. The results demonstrated that the expression level of EPN3 in breast cancer tissues was higher compared with that in adjacent tissues (P<0.05). The expression level of EPN3 in the ER‑positive breast cancer cell line, MCF7, was higher compared with that in the other cell lines (MCF10A, ZR75‑1, MDA‑MB‑231, BT549 and SK‑BR‑3). After knocking down the expression of EPN3 in MCF7 cells, the proliferative ability of the cells was decreased, and the apoptosis rate was increased (P<0.05). After EPN3 knockdown in MCF7 cells, the phosphorylation of NF‑κB was decreased (P<0.05), and the nuclear translocation signal was weakened. Thus, it was suggested that EPN3 promoted cell proliferation and inhibited cell apoptosis by regulating the NF‑κB signaling pathway in ER‑positive breast cancer.
View References

Related Articles

Journal Cover

January-2022
Volume 25 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 3.4
  • Ranked Medicine Research and Experimental
    (total number of cites)
  • CiteScore: 6.9
  • CiteScore Rank: Q2: #98/328 Biochemistry, Genetics and Molecular Biology
  • Source Normalized Impact per Paper (SNIP): 0.721
  • SCImago Journal Rank (SJR): 0.65
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Wu Q, Li Q, Zhu W, Zhang X and Li H: Epsin 3 potentiates the NF‑κB signaling pathway to regulate apoptosis in breast cancer. Mol Med Rep 25: 15, 2022
APA
Wu, Q., Li, Q., Zhu, W., Zhang, X., & Li, H. (2022). Epsin 3 potentiates the NF‑κB signaling pathway to regulate apoptosis in breast cancer. Molecular Medicine Reports, 25, 15. https://doi.org/10.3892/mmr.2021.12531
MLA
Wu, Q., Li, Q., Zhu, W., Zhang, X., Li, H."Epsin 3 potentiates the NF‑κB signaling pathway to regulate apoptosis in breast cancer". Molecular Medicine Reports 25.1 (2022): 15.
Chicago
Wu, Q., Li, Q., Zhu, W., Zhang, X., Li, H."Epsin 3 potentiates the NF‑κB signaling pathway to regulate apoptosis in breast cancer". Molecular Medicine Reports 25, no. 1 (2022): 15. https://doi.org/10.3892/mmr.2021.12531